Table 2.

Levels of fasting blood glucose (FBG) in experimental mice of different groups over the 28-day trial (mean ± SD). Different letters indicate significant differences (p < 0.05 by Duncan’s test) between treatments (n = 6).

Treatment	Fasting blood glucose level (mmol /L)
	0 day	7 day	14 day	21 day	28 day
DC	17.9 ± 0.54 a	19.0 ± 0.46 a	19.2 ± 0.75 a	19.4 ± 0.82 a	20.0 ± 0.73 a
NC	6.6 ± 0.31 b	6.2 ± 0.27 e	6.3 ± 0.27 g	6.1 ± 0.44 g	6.1 ± 0.28 g
EL1	16.8 ± 0.43 a	15.8 ± 0.69 cd	14.9 ± 0.73 bcde	12.0 ± 0.87 cde	10.6 ± 0.48 de
EL2	16.8 ± 0.88 a	15.5 ± 0.35 d	14.2 ± 0.51 cdef	14.3 ± 0.58 b	12.8 ± 0.89 b
EL3	17.8 ± 0.40 a	15.5 ± 0.42 d	13.3 ± 0.95 ef	10.7 ± 0.61 ef	9.8 ± 0.45 ef
EL4	16.8 ± 1.10 a	15.5 ± 0.82 d	13.2 ± 0.93 ef	10.9 ± 1.03 def	10.4 ± 1.20 e
EL5	17.9 ± 1.02 a	15.9 ± 0.71 cd	14.1 ± 0.78 def	13.2 ± 1.20 bc	12.4 ± 1.06 b
AL1	17.4 ± 1.01 a	16.6 ± 0.55b cd	15.0 ± 1.10b cde	13.7 ± 0.98 bc	11.8 ± 1.10 bcd
AL2	17.5 ± 0.78 a	16.3 ± 0.56b cd	15.2 ± 0.87b cde	12.7 ± 1.07 bcd	11.8 ± 1.49 bcd
AL3	18.1 ± 0.60 a	17.7 ± 1.63 ab	15.6 ± 1.30 bcd	13.5 ± 1.27 bc	12.8 ± 1.35 b
AL4	17.4 ± 1.22 a	18.4 ± 1.27 a	16.5 ± 1.16 b	12.4 ± 1.28 bcde	10.8 ± 1.34 cde
AL5	17.1 ± 0.78 a	17.3 ± 1.20 abc	16.2 ± 0.70 bc	13.1 ± 1.28 bc	12.1 ± 1.42 bc
MHT	17.4 ± 0.82 a	15.0 ± 0.85 d	12.6 ± 1.16 f	9.2 ± 0.74 f	8.5 ± 0.66 f
XKP	17.8 ± 0.57 a	15.7 ± 1.06 cd	13.3 ± 1.74 ef	10.8 ± 0.78 def	9.5 ± 0.59 ef